MIR1302-2: A Drug Target / Disease Biomarker (G100302278)
MIR1302-2: A Drug Target / Disease Biomarker
MIR1302-2 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Mir gene family, which encodes a family of transmembrane proteins that are involved in various signaling pathways. One of the functions of MIR1302-2 is to regulate the production of reactive oxygen species (ROS), which can cause damage to cells and contribute to a variety of diseases, including neurodegenerative disorders, fibrosis, and cancer.
In recent years, researchers have become increasingly interested in MIR1302-2 as a potential drug target or biomarker because of its ability to regulate ROS production and its potential to modulate cellular behavior. Studies have shown that MIR1302-2 can interact with a variety of molecules, including transcription factors, signaling pathways, and cellular signaling cascades. This interactivity suggests that MIR1302-2 may play a role in the regulation of cellular processes that are important for human health and disease.
One of the potential benefits of targeting MIR1302-2 is its potential to modulate the production of ROS, which can contribute to a variety of diseases. ROS are highly reactive molecules that can interact with other molecules and cause damage if not properly regulated. Chronic exposure to ROS can contribute to the development and progression of a variety of diseases, including neurodegenerative disorders, cancer, and fibrosis.
MIR1302-2 has been shown to regulate the production of ROS in various cellular contexts. For example, studies have shown that MIR1302-2 can modulate the production of ROS in neurons, heart cells, and other tissues. This regulation is likely important for the function of these cells and may contribute to their health and stability.
Another potential benefit of targeting MIR1302-2 is its potential to serve as a biomarker for disease. The regulation of cellular processes by MIR1302-2 may be disrupted in a variety of diseases, including neurodegenerative disorders, cancer, and fibrosis. By targeting MIR1302-2, researchers may be able to develop new diagnostic tools or therapeutic approaches for these diseases.
MIR1302-2 has also been shown to interact with a variety of molecules, including transcription factors, signaling pathways, and cellular signaling cascades. This interactivity suggests that MIR1302-2 may play a role in the regulation of cellular processes that are important for human health and disease.
Targeting MIR1302-2 may also have the potential to improve the efficacy of certain therapies. For example, MIR1302-2 has been shown to interact with several signaling pathways, including the PI3K/Akt signaling pathway. This suggests that targeting MIR1302-2 may be a way to enhance the effectiveness of drugs that target this pathway, such as certain anti-cancer drugs.
In conclusion, MIR1302-2 is a protein that has the potential to be a drug target or biomarker in various diseases. Its ability to regulate the production of ROS and its potential interactions with other molecules make it an attractive target for research into the regulation of cellular processes and the development of new therapeutic approaches. Further studies are needed to fully understand the role of MIR1302-2 in cellular processes and its potential as a drug target or biomarker.
Protein Name: MicroRNA 1302-2
The "MIR1302-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1302-2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915
